Genetic differences in cytochrome P450 enzymes and antidepressant treatment response
- 20 November 2013
- journal article
- research article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 28 (2) , 133-141
Abstract
Antidepressant response varies between patients, possibly due to differences in the rate cytochrome P450 enzymes metabolise antidepressants into inactive compounds. Drug metabolism rates are influenced by common variants in the genes encoding these enzymes. However, it remains unclear whether treatment outcomes can be predicted by either CYP450 genotype or antidepressant serum concentration. In GENDEP (a pharmacogenetic study of depressed individuals treated with either escitalopram or nortriptyline), serum concentrations of antidepressants and their primary metabolite were measured after eight weeks treatment and variants in CYP2D6 and CYP2C19 were genotyped. Amongst patients taking escitalopram (n=223), the genotype CYP2C19 was significantly associated with escitalopram serum concentrations and desmethylescitalopram:escitalopram ratio. For those taking nortriptyline (n=161), the CYP2D6 genotype was significantly associated with nortriptyline and 10-hydroxynortriptyline serum concentrations and 10-hydroxynortriptyline:nortrip-tyline ratio. CYP450 genotypes conferring greater enzyme activity were linked to lower drug serum concentrations and higher metabolite:drug ratios. Nonetheless, no significant association was found between either CYP450 genotype or antidepressant serum concentration and treatment response. While there is a significant relationship between the CYP450 genotype and serum concentrations of escitalopram and nortriptyline, the genotypes are not predictive of differences in treatment response for either drug. Furthermore, differences in antidepressant serum concentrations are not associated with variability in treatment response.Keywords
This publication has 32 references indexed in Scilit:
- Genetic Predictors of Response to Serotonergic and Noradrenergic Antidepressants in Major Depressive Disorder: A Genome-Wide Analysis of Individual-Level Data and a Meta-AnalysisPLOS Medicine, 2012
- Using a pharmacogenomic algorithm to guide the treatment of depressionTranslational Psychiatry, 2012
- Biomarkers Predicting Treatment Outcome in Depression: What is Clinically Significant?Pharmacogenomics, 2012
- Association Between Citalopram Serum Levels and Clinical Improvement of Patients With Major DepressionJournal of Clinical Psychopharmacology, 2011
- Pharmacokinetic Genes Do Not Influence Response or Tolerance to Citalopram in the STAR*D SamplePLOS ONE, 2008
- Stereoselective Metabolism of Citalopram in Plasma and Cerebrospinal Fluid of Depressive PatientsJournal of Clinical Psychopharmacology, 2004
- CYP2D6 Genotyping with Oligonucleotide Microarrays and Nortriptyline Concentrations in Geriatric DepressionNeuropsychopharmacology, 2001
- Tricyclic Antidepressant Concentrations in PlasmaJournal of Clinical Psychopharmacology, 1994
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979
- Clinical response and plasma concentration of amitriptyline and its metabolite nortriptylineEuropean Journal of Clinical Pharmacology, 1978